Increased concentration of hepatocyte growth factor in the sera of patients with gastrointestinal cancer.
We measured the concentration of hepatocyte growth factor (HGF) in the sera of 138 patients with gastrointestinal cancer. The mean value and positive rate for this protein (assuming 0.4 ng/ml as the cut-off value) were 0.29 ng/ml (11.4%) in healthy donors (n=44), 0.90 ng/ml(70.8%) in esophageal cancer (n=24), 0.39 ng/ml (33.3%) in gastric cancer (n=39), and 0.40 ng/ml (42.7%) in colorectal cancer (n=75). Thus, the mean values of the esophageal and colorectal cancer group were significantly higher than that of healthy donors. There was a tendency for elevated mean value of serum HGF in the sera of patients with distant metastases, compared to those with no such evidence, i.e., 1.36:0.77 ng/ml in esophageal cancer, 0.69:0.30 ng/ml in gastric cancer, and 0.66:0.37 ng/ml in colorectal cancer. This difference was statistically significant in gastric and colorectal cancer. These findings suggest that serum HGF is useful as a tumor marker with a close correlation to the metastatic state of gastrointestinal cancer.